Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.

Chay WY, Chew SH, Ong WS, Busmanis I, Li X, Thung S, Ngo L, Lim SL, Lim YK, Chia YN, Koh E, Pang C, Soh LT, Wang J, Ho TH, Tay SK, Lim-Tan SK, Lim KH, Chia JW, Goh LK.

PLoS One. 2013 Apr 19;8(4):e61565. doi: 10.1371/journal.pone.0061565. Print 2013.

2.

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff BJ, Kalloger SE, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia JJ, Schoolmeester JK, Bakkum-Gamez J, Tinker AV, Bowtell DD, Huntsman DG, Gilks CB, McAlpine JN.

J Pathol. 2013 Jan;229(1):111-20. doi: 10.1002/path.4088.

PMID:
22899400
3.

Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.

Lin WL, Kuo WH, Chen FL, Lee MY, Ruan A, Tyan YS, Hsu JD, Chiang H, Han CP.

Ann Surg Oncol. 2011 Aug;18(8):2388-94. doi: 10.1245/s10434-011-1572-z. Epub 2011 Feb 23.

PMID:
21347793
4.

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM.

BMC Cancer. 2009 Dec 10;9:433. doi: 10.1186/1471-2407-9-433.

5.

Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.

He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q.

World J Gastroenterol. 2013;19(14):2171-8. doi: 10.3748/wjg.v19.i14.2171.

6.

Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.

Chao WR, Lee MY, Lin WL, Koo CL, Sheu GT, Han CP.

Am J Surg Pathol. 2014 Sep;38(9):1227-34. doi: 10.1097/PAS.0000000000000268.

PMID:
25133707
7.

HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.

Chao WR, Lee MY, Lin WL, Chen CK, Lin JC, Koo CL, Sheu GT, Han CP.

Hum Pathol. 2014 Apr;45(4):810-6. doi: 10.1016/j.humpath.2013.11.016. Epub 2013 Dec 12.

PMID:
24656091
8.
9.

HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target.

Han CP, Hsu JD, Yao CC, Lee MY, Ruan A, Tyan YS, Yang SF, Chiang H.

Histopathology. 2010 Nov;57(5):763-4. doi: 10.1111/j.1365-2559.2010.03689.x. No abstract available. Erratum in: Histopathology. 2011 Feb;58(3):506.

PMID:
21083606
11.

HER2 expression in ovarian mucinous carcinomas in Tunisia.

Missaoui N, Abdelkarim SB, Ayachi M, Hmissa S, Yaacoubi MT.

Asian Pac J Cancer Prev. 2014;15(19):8121-5.

12.
13.

RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.

Zou Y, Wang F, Liu FY, Huang MZ, Li W, Yuan XQ, Huang OP, He M.

Gene. 2013 Nov 15;531(1):112-6. doi: 10.1016/j.gene.2013.08.054. Epub 2013 Aug 31.

PMID:
24001777
14.

[Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma].

Wu HM, Liu YH, Lin F, Xu FP, Luo DL, Zhang F, Zhuang HG, Luo XL, Wu WL, Lin XT.

Zhonghua Bing Li Xue Za Zhi. 2011 May;40(5):296-9. Chinese.

PMID:
21756821
15.

Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?

Wong FY, Yip CS, Chua ET.

World J Surg. 2012 Feb;36(2):287-94. doi: 10.1007/s00268-011-1353-7.

PMID:
22105650
16.

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.

Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, Putti T, Salto-Tellez M, Lim GS.

J Clin Pathol. 2011 Dec;64(12):1097-101. doi: 10.1136/jclinpath-2011-200082. Epub 2011 Sep 6.

PMID:
21896578
17.

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.

Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A.

BMC Cancer. 2008 Sep 1;8:252. doi: 10.1186/1471-2407-8-252.

18.

MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.

Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB, Feng Q.

World J Surg Oncol. 2012 Aug 27;10:174.

19.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232
20.

Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.

Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO.

BMC Cancer. 2011 Jul 12;11:292. doi: 10.1186/1471-2407-11-292.

Supplemental Content

Support Center